Showing results (131-140 of 150) with videos related to
Sort By:
Pageof 15
Future Oncology (London, England)|January 19, 2023
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS dataParneet Cheema, Byoung Chul Cho, Helano Freitas, et al.BMC Medicine|April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studiesXingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.Lancet (London, England)|January 16, 2026
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trialShun Lu, Jie Wang, Nong Yang, et al.Future Oncology (London, England)|October 30, 2025
Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational studyHua Zhong, Shunjun Jiang, Wenxiu Yao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.Cell Host & Microbe|July 10, 2025
Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinomaHuan Yu, Yang Du, Yuling He, et al.Ebiomedicine|March 26, 2025
Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre studyBo Jia, Shuo Wang, Fengyuan Zhang, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Cancer Communications (London, England)|October 26, 2021
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical studyJie Zhang, Yueyin Pan, Qin Shi, et al.Pageof 15